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Abstract 
 
Objective: To investigate the potential value of biophysical and biochemical markers at 30-34 
weeks’ gestation in the prediction of adverse perinatal outcome.  
 
Methods: Screening study in 8,268 singleton pregnancies at 30-34 weeks. Estimated fetal 
weight (EFW), uterine artery pulsatility index (PI), umbilical artery PI, fetal middle cerebral 
artery (MCA) PI, mean arterial pressure (MAP), serum placental growth factor (PLGF) and 
soluble fms-like tyrosine kinase-1 (sFlt-1) were measured. The detection rate (DR) and false 
positive rate (FPR) of screening by each biomarker were estimated for stillbirth, 
preeclampsia, delivery of small for gestational age (SGA) neonate, cesarean section for fetal 
distress before or during labor, umbilical arterial cord blood pH <7.0 or umbilical venous 
blood pH <7.1, Apgar score <7 at 5 minutes and admission to the neonatal unit (NNU).  
 
Results: Multivariable regression analysis demonstrated that significant prediction of PE was 
provided by PLGF, sFlt-1, MAP and MCA PI with DR of 98% of PE delivering at <37 weeks’ 
gestation and 56% of those delivering at >37 weeks, at 10% FPR. Prediction of SGA was 
provided by EFW, PLGF, sFlt-1, uterine artery PI, umbilical artery PI, and MCA PI with DR of 
88% of SGA at <37 and 51% at >37 weeks’ gestation, at 10% FPR. Prediction of stillbirth 
was provided by EFW, uterine artery PI and MCA PI with DR of 30% at 10% FPR. Prediction 
of cesarean section for fetal distress before labor was provided by EFW, sFlt-1, uterine 
artery PI and umbilical artery PI with DR of 90%, at 10% FPR. Prediction of fetal distress in 
labor was provided by EFW and sFlt-1 with DR of 16%, at 10% FPR. There were no 
significant differences from the normal outcome group in any of the biomarkers for low cord 
blood pH, low Apgar score or NNU admission for cases other than those with PE and / or 
SGA. 
 
Conclusion: At 30-34 weeks’ gestation, biomarkers of impaired placentation and fetal 
hypoxemia provide good prediction of PE, SGA and fetal distress before labor, but poor or no 
prediction of stillbirth and adverse events in labor or after birth. 
  
Introduction 
 
Impaired placentation, reflected in increased pulsatility index (PI) in the uterine arteries, 
reduced serum placental growth factor (PLGF) and increased soluble fms-like tyrosine 
kinase-1 (sFlt-1), is associated with subsequent development of preeclampsia (PE) and birth 
of small for gestational age (SGA) neonates [1,2]. Another marker of development of PE is 
increased mean arterial pressure (MAP) [1,2]. Impaired placentation is also associated with 
fetal hypoxemia and consequent redistribution in the fetal circulation, reflected in reduced 
fetal middle cerebral artery (MCA) PI and increased umbilical artery PI [3-10]. 
 
A screening study at 30-34 weeks’ gestation, involving more than 30,000 singleton 
pregnancies, reported that the incidence of adverse perinatal outcome is higher in SGA than 
in non-SGA fetuses, but the majority of cases for each adverse event are in the non-SGA 
group, including about 70% of stillbirths and more than 80% of cases of cesarean section for 
fetal distress, low cord blood pH and low 5 minute Apgar score [11]. This is analogous to 
screening for Down syndrome where the risk in women aged >35 years is substantially 
higher than in younger women but the overall contribution of the latter group is more than 
twice as high as that of the older age group. It could therefore be argued that the objective of 
prenatal screening should be identification of pregnancies with impaired placentation and 
fetal hypoxemia, irrespective of fetal size. 
 
The objective of this screening study is to investigate the potential value of uterine artery PI, 
umbilical artery PI, MCA PI, MAP and serum PLGF and sFlt-1, at 30-34 weeks’ gestation, in 
the prediction of adverse perinatal outcome, including development of PE, birth of SGA 
neonate, stillbirth, cesarean section for fetal distress before or during labor, umbilical arterial 
cord blood pH <7.0 or umbilical venous blood pH <7.1, Apgar score <7 at 5 minutes and 
admission to the neonatal unit (NNU). 
 
 
Methods 
 
The data for this study were derived from prospective screening for adverse obstetric 
outcomes in women attending for their routine hospital visit in the third trimester of 
pregnancy at King’s College Hospital, London, University College London Hospital, London 
and Medway Maritime Hospital, Kent, between May 2011 and August 2014. This visit, which 
was held at 30+0-34+6 weeks’ gestation, included recording of maternal characteristics and 
medical history, estimation of fetal size from transabdominal ultrasound measurement of 
fetal head circumference, abdominal circumference and femur length. Gestational age was 
determined by the measurement of fetal crown-rump length at 11-13 weeks or the fetal head 
circumference at 19-24 weeks [12,13]. Transabdominal color flow mapping was used to 
visualize the uterine arteries, umbilical arteries and fetal MCA [14-16]. Pulsed-wave Doppler 
was then used to obtain waveforms and when three similar consecutive waveforms were 
obtained the PI was measured.  
 
Written informed consent was obtained from the women agreeing to participate in a study on 
adverse pregnancy outcome, which was approved by the Ethics Committee of each 
participating hospital. The pregnancies included in the study were those with data on all 
eight biomarkers resulting in live birth or stillbirth of phenotypically normal babies at >24 
weeks’ gestation. 
 
Patient characteristics  
 
Patient characteristics recorded included maternal age, racial origin (Caucasian, Afro-
Caribbean, South Asian, East Asian and mixed), method of conception (spontaneous, use of 
ovulation drugs or in vitro fertilization), cigarette smoking during pregnancy  (yes or no), 
medical history of chronic hypertension (yes or no), diabetes mellitus (yes or no), systemic 
lupus erythematosus (SLE) or anti-phospholipid syndrome (APS) and parity (parous or 
nulliparous if no previous pregnancies at > 24 weeks). Maternal weight and height were 
measured. 
 
Outcome measures 
 
Data on pregnancy outcome were collected from the hospital maternity records or the 
general medical practitioners of the women. The outcome measures of the study were 
stillbirth, cesarean section for fetal distress in labor, umbilical arterial cord blood pH <7.0 or 
venous blood pH <7.1, Apgar score <7 at 5 minutes and admission to NNU. The newborn 
was considered to be SGA if the birth weight was less than the 10th percentile after 
correction for gestational age at delivery [17]. The birth weight Z-score was also derived from 
the normal range for gestational age [17]. The definition of PE was that of the International 
Society for the Study of Hypertension in Pregnancy [18].  
 
Statistical analysis 
 
Comparison between the outcome groups was by χ2-test or Fisher’s exact test for 
categorical variables and Mann Whitney-U test for continuous variables. Categorical data 
are presented as n (%) and continuous data as median and interquartile range (IQR).   
 
The measured values of uterine artery PI, umbilical artery PI, MCA PI, MAP, PLGF and sFlt-
1 were expressed as multiple of the median (MoM) after adjustment for variables from 
maternal characteristics and medical history that affect these measurements [9-23]. 
Univariable and multivariable logistic regression analysis was used to determine if log10 MoM 
of each biomarker had a significant contribution in predicting each adverse outcome. The 
detection rate (DR) and false positive rate (FPR) of screening were estimated for each 
adverse outcome. The performance of screening was determined by receiver operating 
characteristic (ROC) curves analysis. 
 
The statistical software package SPSS 22.0 (IBM SPSS Statistics for Windows, Version 
22.0. Armonk, NY: IBM Corp, 2013) was used for the data analyses. 
 
 
Results 
 
Study population 
 
The characteristics of the study population and the various subgroups according to outcome 
are given in Table 1.  
 
Biomarkers in pregnancies with stillbirths, PE or birth of SGA neonates 
 
The median MoM values of biomarkers and percentage of values above or below a 
percentile for pregnancies resulting in stillbirth, PE or birth of SGA neonates with birth weight 
<10th percentile are compared to the unaffected pregnancies by any one of these adverse 
outcomes are shown in Table 2. 
 
Stillbirth occurred in 23 (0.28%) pregnancies and in 8 (34.8%) of these the birth weight was 
below the 10th percentile. In the pregnancies resulting in stillbirth, compared to the 
unaffected group, there were no significant differences in median MoM values of any of the 
seven biomarkers (Table 2). However, there was a non-significant tendency for lower PLGF, 
higher sFlt-1, higher uterine artery PI, lower MCA PI and lower EFW. Multivariable logistic 
regression analysis demonstrated that significant contributions for stillbirth were provided by 
EFW, uterine artery PI and MCA PI (AUROC curve 0.683, 95% CI 0.568-0.797) (Table 3). 
The DR of stillbirth by combined screening, at FPR of 10%, was 30.4% (Figure 1). 
 
Preeclampsia occurred in 223 (2.7%) pregnancies, including 40 (17.9%) in which delivery 
was at <37 weeks. In the pregnancies that developed PE, compared to the unaffected 
group, there was lower PLGF, higher sFlt-1, higher uterine artery PI and MAP and lower 
MCA PI and EFW; the differences from normal were nore marked in the group of PE 
delivering at <37 weeks’ gestation than in those delivering at >37 weeks (Table 2). 
Multivariable logistic regression analysis demonstrated that significant contributions for PE 
<37 weeks were provided by PLGF, sFlt-1, uterine artery PI and MAP (AUROC curve 0.992, 
95% CI 0.985-1.000) and contributions for PE >37 weeks were provided by PLGF, sFlt-1, 
MCA PI and MAP (AUROC curve 0.808, 95% CI 0.772-0.844) (Table 3). The DR of 
combined screening by all significant contributors, at FPR of 10%, was 97.5% for PE <37 
weeks and 55.8% for PE >37 weeks (Figure 1). 
 
In livebirths the birth weight was below the 10th percentile in 822 (9.9%) cases. In the 
pregnancies with SGA neonates, compared to the unaffected group, there was lower PLGF, 
MCA PI and EFW and higher sFlt-1, uterine artery PI, umbilical artery PI and MAP; the 
differences from normal were nore marked in the group of SGA delivering at <37 weeks’ 
gestation than in those delivering at >37 weeks (Table 2). Multivariable logistic regression 
analysis demonstrated that significant contributions for SGA <37 weeks were provided by 
EFW, PLGF, sFlt-1 and uterine artery PI (AUROC curve 0.954, 95% CI 0.930-0.978) and 
contributions for SGA >37 weeks were provided by EFW, PLGF, sFlt-1, uterine artery PI, 
umbilical artery PI and MCA PI (AUROC curve 0.829, 95% CI 0.813-0.844) (Table 3). The 
DR of combined screening by all significant contributors, at FPR of 10%, was 88.3% for SGA 
<37 weeks and 51.0% for SGA >37 weeks (Figure 1). 
 
Biomarkers in pregnancies delivered by cesarean section for fetal distress 
 
In the 8,245 pregnancies with live births, there were 6,263 with vaginal delivery following 
spontaneous or induced labor, 873 with elective cesarean section for a variety of indications 
and 1,109 with cesarean section following spontaneous or induced labor; in the latter group 
the indication for cesarean section was fetal distress in 512 cases. In the elective cesarean 
section group (n=873) there were a variety of indications, including breech or transverse lie 
(n=191), placenta previa (n=41), previous cesarean section, traumatic birth or maternal 
request (n=567), maternal medical disorder (n=44) and SGA fetuses with fetal compromise 
diagnosed by abnormal fetal heart rate patterns or fetal Doppler indices (n=30).  
 
The median MoM values of biomarkers and percentage of values above or below a 
percentile for pregnancies resulting in delivery by cesarean section for fetal distress before 
labor (n=30) or during labor (n=512) and those delivering vaginally are shown in Table 4.  
 
In the group with cesarean section for fetal distress before labor, compared to those 
delivering vaginally, there was lower EFW, PLGF and MCA PI and higher sFlt-1, uterine 
artery PI, umbilical artery PI and MAP; the values were >90th or <10th percentile, depending 
on the biomarker, in 43-90% of the cases (Table 4). Multivariable logistic regression analysis 
demonstrated that significant contribution to elective cesarean section for fetal distress was 
provided by EFW, sFlt-1, uterine artery PI and umbilical artery PI (AUROC curve 0.972, 95% 
CI 0.944-0.999); the DR at 10% FPR, was 90.0% (Table 5, Figure 1).  
 
In the group with cesarean section for fetal distress in labor, compared to those delivering 
vaginally, there was higher sFlt-1, but no significant differences in median value of the other 
biomarkers. Multivariable logistic regression analysis demonstrated that significant 
contribution to cesarean section for fetal distress was provided by EFW and sFlt-1 (AUROC 
curve 0.556, 95% CI 0.530-0.582); the DR at 10% FPR, was 16.2% (Table 5, Figure 1).   
Biomarkers in pregnancies with adverse outcome after delivery 
 
The median MoM values of biochemical and biophysical markers and percentage of values 
above or below a percentile in pregnancies with and without low cord blood pH, low Apgar 
score at 5 minutes and admission to the neonatal unit are shown in Table 6. 
 
In the group with low cord blood pH compared to those with normal pH and in those with low 
5 minute Apgar score compared to those with normal score, there were no significant 
differences in the median MoM values of any of the biomarkers. In the group with NNU 
admission, compared to those without admission, there was lower PLGF and higher sFlt-1 
and uterine artery PI. Multivariable logistic regression analysis demonstrated that significant 
contribution to NNU admission was provided by all three biomarkers (AUROC curve 0.592, 
95% CI 0.566-0.619); the DR at 10% FPR, was 24.8%  (Table 7). However, when the cases 
of PE and those with SGA neonates were excluded, none of the biomarkers provided 
significant contribution in the prediction of NNU admission.  
 
 
Discussion 
 
Main findings of the study 
 
The findings of this study demonstrate that in pregnancies that develop PE and those that 
result in delivery of SGA neonates there is biophysical and biochemical evidence of impaired 
placentation reflected in increased uterine artery PI and serum sFlt-1 and reduced serum 
PLGF. In such cases of impaired placentation the EFW is reduced and there is also evidence 
of fetal hypoxemia reflected in low fetal MCA PI and high umbilical artery PI. The deviation 
from normal for the biophysical and biochemical markers is more marked in the most severe 
cases of PE and SGA requiring iatrogenic preterm delivery. Screening by a combination of 
biomarkers at 32 weeks’ gestation predicted 98% of preterm PE and 56% of term PE, at 
FPR of 10%; the respective values for SGA in the absence of PE were 88% and 51%.   
 
Impaired placentation and fetal hypoxemia are also observed in some of the pregnancies 
resulting in stillbirth, in those developing fetal distress in labor necessitating delivery by 
caesarean section and in those requiring admission to NNU. However, the performance of 
screening with biomarkers at 32 weeks’ gestation for these complications is poor with 
respective DRs of 30%, 16% and 25%, at FPR of 10%. Biomarker testing at 32 weeks was 
not useful in prediction of low cord blood pH, low Apgar score, or NNU admission for cases 
other than those with PE and / or SGA. 
 
Strengths and limitations of the study 
 
The strengths of this third-trimester screening study are first, examination of a large 
population of pregnant women attending for routine care at a gestational age range which is 
widely used for the assessment of fetal growth and wellbeing, second, use of a specific 
methodology and appropriately trained doctors to measure MAP and carry out the Doppler 
studies, third, use of automated machines to prospectively obtain reproducible 
measurements of serum PLGF and sFlt-1, fourth, estimate MoM values for biophysical and 
biochemical markers after adjustment for factors that affect the measurements, and fifth, 
examine a wide range of well accepted indicators of adverse perinatal outcome. 
 
The main limitation of the study is that the results of the 30-34 weeks’ scan were made 
available to the obstetricians of the patients who would have taken specific actions on further 
monitoring and delivery for the cases of suspected SGA with abnormal Doppler findings. 
Consequently, the performance of screening for adverse perinatal outcomes by biomarkers 
of impaired placentation and fetal hypoxemia would have been negatively biased. It is likely 
that at least some of the cases of SGA and fetal distress that were delivered by elective 
cesarean section would have resulted in stillbirth, fetal distress in labor and low cord blood 
pH had they not been detected by the routine assessment at 32 weeks. In our study there 
were 30 pregnancies with SGA fetuses that were delivered by elective cesarean section 
because of abnormal fetal heart rate patterns or fetal Doppler indices and this number is not 
negligible by comparison with the number of pregnancies with stillbirths and birth weight 
below the 10th percentile (n=8). 
 
Comparison with findings from previous studies 
 
There are no previous third-trimester screening studies of a routine population for adverse 
perinatal events. In previous screening studies at 30-34 weeks’ gestation we used Bayes 
theorem to combine maternal characteristics and medical history with biophysical and 
biochemical markers and reported that the DR, at 10% FPR, was 99% for preterm-PE, 89% 
for preterm-SGA, 75% for term-PE and 57% for term-SGA [21,22]. 
 
Implications for clinical practice 
 
An integrated clinic at 32 weeks’ gestation, which includes measurement of biomarkers, 
identifies nearly all cases that will develop PE and those delivering SGA neonates at <37 
weeks’ gestation and the majority of cases with these complications delivering at term. 
Performance of screening by combining biophysical and biochemical markers is superior to 
screening by either group of markers alone. The performance of screening for stillbirth is 
poor but this is likely to be underestimated because identification of cases with impaired 
placentation and fetal hypoxemia and their timely delivery would have prevented some of the 
stillbirths. 
 
In pregnancies without SGA or PE, combined screening at 32 weeks is not useful in the 
prediction of adverse events during labor or after birth. The extent to which the performance 
of screening is improved by assessment at 36 rather than 32 weeks remains to be 
determined. 
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Figure legends 
 
Figure 1. Receiver operating characterist curves for prediction of preeclampsia (PE) 
delivering at <37 and >37 weeks’ gestation, small for gestational age (SGA) neonates 
delivering at <37 and >37 weeks’ gestation, fetal distress resulting in delivery by cesarean 
section before and during labor, stillbirth and neonatal unit (NNU) admission. 
 
Table 1. Maternal and pregnancy characteristics of the study population and subgroups of stillbirth, preeclampsia, small for gestational age 
neonates, fetal distress in labor leading to cesarean section, low umbilical arterial or venous cord blood pH, low 5-minute Apgar score and 
admission to the neonatal unit. In each group the data are compared to the cohort without the outcome measure. 
 
 
All pregnancies 
(n=8,268) 
Stillbirth 
(n=23) 
Preeclampsia 
(n=223) 
Small for gestation 
(n=822) 
Fetal distress 
(n=512) 
Low cord pH 
(n=84) 
Low Apgar score 
(n=70) 
NNU admission 
(n=524) 
Maternal characteristics         
Maternal age (years) 31.0 (26.6-34.7) 32.9 (23.2-37.2) 31.5 (26.8-34.8) 29.7 (25.2-34.2)** 31.2 (27.0-35.9) 32.1 (27.1-35.5) 31.9 (26.5-35.6) 30.9 (26.4-35.0) 
Maternal weight (Kg) 77.0 (68.7-87.8) 89.0 (66.2-100.5) 83.8 (72.0-97.5)** 71.8 (64.0-81.0)** 81.2 (72.0-93.0)** 78.8 (73.3-88.7) 81.9 (71.0-91.1) 79.2 (70.8-92.0)** 
Maternal height (m) 1.65 (1.60-1.69) 1.65 (1.61-1.68) 1.64 (1.59-1.69) 1.63 (1.58-1.67)** 1.63 (1.59-1.68)** 1.64 (1.59-1.68) 1.62 (1.60-1.67) 1.64 (1.60-1.69) 
Cigarette smoker 827 (10.0) 3 (13.0) 13 (5.8) 148 (18.0)** 46 (9.0) 7 (8.3) 8 (11.4) 67 (12.8) 
Racial origin         
Caucasian 6,185 (74.8) 16 (69.6) 138 (61.9) 530 (64.5) 337 (65.8) 67 (79.8) 41 (58.6) 396 (75.6) 
Afro-Caribbean 1,437 (17.4) 5 (21.7) 69 (30.9)** 191 (23.2)** 130 (25.4)** 11 (13.1) 23 (32.9)* 101 (19.3) 
South Asian 312 (3.8) 1 (4.3) 10 (4.5) 56 (6.8)** 27 (5.3) 4 (4.8) 2 (2.9) 12 (2.3) 
East Asian 150 (1.8) 1 (4.3) 4 (1.8) 13 (1.6) 11 (2.1) 0 (0.0) 1 (1.4) 6 (1.1) 
Mixed 184 (2.2) 0 (0.0) 2 (0.9) 32 (3.9)* 7 (1.4) 2 (2.4) 3 (4.3) 9 (1.7) 
Conception         
Spontaneous 7,996 (96.7) 22 (95.7) 215 (96.4) 799 (97.2) 485 (94.7) 83 (98.8) 68 (97.1) 500 (95.4) 
Assisted conception 272 (3.3) 1 (4.3) 8 (3.6) 23 (2.8) 27 (5.3)* 1 (1.2) 2 (2.9) 24 (4.6) 
Medical disorder         
Chronic hypertension 121 (1.5) 1 (4.3) 30 (13.5)** 10 (1.2) 13 (2.5) 1 (1.2) 3 (4.3) 13 (2.5) 
SLE / APS 15 (0.2) 0 (0.0) 0 (0.0) 1 (0.1) 2 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 
Diabetes mellitus 80 (1.0) 0 (0.0) 2 (0.9) 7 (0.9) 8 (1.6) 0 (0.0) 1 (1.4) 19 (3.6)** 
Obstetric history         
Parous 4,198 (50.8) 10 (43.5) 91 (40.8) 324 (39.4) 146 (28.5) 39 (46.4) 36 (51.4) 216 (41.2) 
Nulliparous 4,070 (49.2) 13 (56.5) 132 (59.2)* 498 (60.6)** 366 (71.5)** 45 (53.6) 34 (48.6) 308 (58.8)** 
Pregnancy complication         
Gestational diabetes 215 (2.6) 2 (8.7) 13 (5.8)* 19 (2.3) 19 (3.7) 7 (8.3)* 3 (4.3) 32 (6.1)** 
SROM 455 (5.5) 0 (0.0) 4 (1.8) 52 (6.3) 69 (13.5)** 4 (4.8) 3 (4.3) 53 (10.1)** 
Labor and delivery         
 
SLE= systemic lupus erythematosus; APS = anti-phospholipid syndrome; SROM = Spontaneous rupture of membranes; VD = vaginal delivery; CS = cesarean 
section; GA = gestational age  
 
Significance value adjusted for multiple comparisons with post hoc Bonferonni correction * = p<0.01; ** = p<0.001 
Spontaneous labor,  VD 5,353 (64.7) 8 (34.8) 37 (16.6) 514 (62.5) 0 (0.0) 41 (48.8) 26 (37.1) 246 (46.9) 
Spontaneous labor, CS 765 (9.3) 0 (0.0) 12 (5.4) 65 (7.9) 355 (64.5)** 19 (22.6) 12 (17.1) 94 (17.9)** 
Induced labor, VD 931 (11.3) 13 (56.5)** 89 (39.9)** 127 (15.5)** 0 (0.0) 9 (10.7) 9 (12.9) 60 (11.5) 
Induced labor, CS 344 (4.2) 0 (0.0) 38 (17.0)** 46 (5.6)* 177 (34.6)** 9 (10.7) 12 (17.1)** 53 (10.1)** 
Elective CS 875 (10.6) 2 (8.7) 47 (21.1)** 70 (8.5) 0 (0.0) 6 (7.1) 11 (15.7) 71 (13.5) 
Assessment         
GA at assessment (wks) 32.2 (32.0-32.5) 32.2 (32.0-32.4) 32.1 (32.0-32.4) 32.1 (32.0-32.5) 32.2 (32.0-32.6) 32.1 (32.0-32.4) 32.2 (32.0-32.5) 32.2 (32.0-32.5) 
EFW (percentile) 53.3 (28.9-77.6) 42.5 (16.5-71.9) 48.9 (20.9-75.7)** 18.1 (6.9-37.0)** 56.0 (31.7-80.4) 55.1 (29.6-73.6) 56.8 (23.5-86.5) 54.9 (24.7-78.3) 
Outcome         
GA at delivery (wks) 40.0 (39.0-40.9) 38.3 (36.9-40.7)* 38.6 (37.3-40.2)** 39.9 (38.9-40.9) 40.6 (39.4-41.4)** 40.0 (38.5-40.9) 39.9 (38.4-41.2) 39.0 (36.8-40.6)** 
BW  (percentile) 48.5 (23.7-74.4) 32.7 (4.3-75.2)** 35.0 (9.8-65.8)** 5.3 (2.7-7.8)** 41.9 (16.2-71.5)** 49.8 (19.0-78.4) 52.5 (15.4-83.0) 44.5 (18.4-77.8) 
Table 2. Biochemical and biophysical markers in pregnancies resulting in stillbirth, preeclampsia, birth of small for gestational age neonates 
and those unaffected by any of these adverse outcomes. 
 
Unaffected 
(n=7,207) 
Stillbirth 
(n=23) 
PE < 37 wks 
(n=40) 
PE > 37 wks 
(n=183) 
SGA < 37 wks 
(n=60) 
SGA > 37 wks 
(n=762) 
Biochemical markers       
PlGF (MoM), median (IQR) 1.01 (0.63-1.57) 0.63 (0.45-1.31) 0.13 (0.02-0.22)*** 0.41 (0.28-0.78)*** 0.33 (0.16-0.61)*** 0.64 (0.38-1.06)*** 
PlGF < 5th percentile, n (%) 224 (3.1) 1 (4.3) 31 (77.5)*** 41 (22.4)*** 25 (41.7)*** 93 (12.2)*** 
PlGF < 10th percentile, n (%) 534 (7.4) 2 (8.7) 36 (90.0)*** 69 (37.7)*** 31 (51.7)*** 156 (20.5)*** 
       
sFlt -1 (MoM), median (IQR) 0.99 (0.74-1.34) 1.21 (0.64-1.95) 4.54 (3.05-6.47)*** 1.43 (0.94-2.20)*** 1.43 (1.06-3.13)*** 1.10 (0.78-1.52)*** 
sFlt > 95th percentile, n (%) 265 (3.7) 2 (8.7) 32 (80.0)*** 45 (24.6)*** 19 (31.7)*** 52 (6.8)*** 
sFlt > 90th percentile, n (%) 602 (8.4) 6 (26.1)** 35 (87.5)*** 62 (33.9)*** 22 (36.7)*** 102 (13.4)*** 
Biophysical markers       
Ut PI (MoM), median (IQR) 0.99 (0.85-1.16) 1.13 (1.00-1.31) 1.60 (1.19-2.10)*** 1.02 (0.85-1.28) 1.08 (0.97-1.49)*** 1.04 (0.91-1.28)*** 
Ut PI > 95th percentile, n (%) 294 (4.1) 3 (13.0) 20 (50.0)*** 19 (10.4)*** 12 (20.0)*** 68 (8.9)** 
Ut PI > 90th percentile, n (%) 618 (8.6) 4 (17.4) 24 (60.0)*** 33 (18.0)*** 19 (31.7)*** 131 (17.2)*** 
       
UA PI (MoM), median (IQR) 1.01 (0.91-1.12) 1.02 (0.86-1.13) 1.08 (0.88-1.17) 0.99 (0.92-1.10) 1.16 (1.01-1.23)*** 1.06 (0.95-1.17)*** 
UA PI > 95th percentile, n (%) 317 (4.4) 1 (4.3) 4 (10.0) 6 (3.3) 14 (23.3)*** 72 (9.4)*** 
UA PI > 90th percentile, n (%) 664 (9.2) 1 (4.3) 5 (12.5) 17 (9.3) 15 (25.0)*** 125 (16.4)*** 
       
MCA PI (MoM), median (IQR) 1.02 (0.92-1.12) 0.95 (0.86-1.01) 1.01 (0.93-1.12) 0.99 (0.87-1.09)** 0.96 (0.87-1.06)** 1.00 (0.90-1.10)** 
MCA PI < 5th percentile, n (%) 339 (4.7) 2 (8.7) 2 (5.0) 18 (9.8)** 5 (8.3) 48 (6.3) 
MCA PI < 10th percentile, n (%) 668 (9.5) 4 (17.4) 4 (10.0) 30 (16.4)** 8 (13.3) 95 (12.5) 
       
MAP (MoM), median (IQR) 1.00 (0.94-1.05) 1.01 (0.97-1.09) 1.16 (1.10-1.26)*** 1.08 (1.00-1.13)*** 1.03 (0.97-1.11)*** 1.01 (0.96-1.06)*** 
MAP > 95th percentile, n (%) 279 (3.9) 1 (4.3) 26 (65.0)*** 40 (21.9)*** 11 (18.3)*** 46 (6.0)** 
MAP > 90th percentile, n (%) 606 (8.4) 2 (8.7) 29 (72.5)*** 63 (34.4)*** 14 (23.3)*** 90 (11.8)** 
       
EFW centile, median (IQR) 57.3 (33.5-79.4) 42.5 (16.5-71.9) 15.6 (1.0-52.2)*** 55.0 (29.0-77.5) 4.5 (0.2-18.2)*** 19.1 (8.0-38.1)*** 
EFW < 5th percentile, n (%) 144 (2.0) 2 (8.7) 12 (30.0)*** 7 (3.8) 31 (51.7)*** 135 (17.7) 
EFW < 10th percentile, n (%) 331 (4.6) 4 (17.4) 17 (42.5)*** 13 (7.1) 38 (63.3)*** 228 (29.9)*** 
PE = preeclampsia; SGA = small for gestational age neonate with birth weight below the 10th percentile. PLGF = placental growth factor; sFlt-1  = soluble fms-like tyrosine 
kinase-1; Ut PI = uterine artery pulsatility index; UA PI = umbilical artery pulsatility index; MCA PI = middle cerebral artery pulsatility index; MAP = mean arterial pressure; EFW 
= estimated fetal weight.  Significance value adjusted for multiple comparisons with post hoc Bonferonni correction ** p<0.01; *** p<0.0001 
Table 3. Univariable and multivariable logistic regression analysis in prediction of stillbirth, preeclampsia and birth of small for gestational age 
fetuses from biochemical and biophysical markers 
 
 
EFW = estimated fetal weight;  PLGF = placental growth factor; sFlt-1  = soluble fms-like tyrosine kinase-1; Ut PI = uterine artery pulsatility index; UA PI = umbilical artery 
pulsatility index; MCA PI = middle cerebral artery pulsatility index; MAP = mean arterial pressure.   
 
 
 
 
Stillbirth Preeclampsia Small for gestation 
Univariable analysis Multivariable analysis Univariable analysis Multivariable analysis Univariable analysis Multivariable analysis 
OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value 
EFW Z-score 
0.63 
(0.42-0.95) 
0.028 
0.66 
(0.44-0.99) 
0.037 
0.70 
(0.61-0.81) 
<0.0001   
0.28 
(0.25-0.30) 
<0.0001 
0.29 
(0.26-0.32) 
<0.0001 
PlGF (Log10 MoM) 
0.32 
(0.09-1.15) 
0.080   
0.02 
(0.01-0.03) 
<0.0001 
0.10 
(0.06-0.15) 
<0.0001 
0.13 
(0.10-0.16) 
<0.0001 
0.20 
(0.15-0.26) 
<0.0001 
sFlt -1 (Log10 MoM) 
3.04 
(0.43-21.68) 
0.267   
123.8 
(70.1-218.8) 
<0.0001 
17.42 
(9.0-33.72) 
<0.0001 
3.80 
(2.70-5.36) 
<0.0001 
1.73 
(1.18-2.56) 
0.005 
Ut PI (Log10 MoM) 
75.41 
(2.79-2.0e03) 
0.010 
51.89 
(2.10-12.8e02) 
0.016 
40.8 
(13.6-122.4) 
<0.0001   
18.48 
(9.88-34.56) 
<0.0001 
8.39 
(4.17-16.91) 
<0.0001 
UA PI (Log10 MoM) 
0.13 
(0.00-67.44) 
0.520   
0.85 
(0.11-6.81) 
0.880   
160.1 
(49.3-520.2) 
<0.0001 
24.28 
(6.51-90.60) 
<0.0001 
MCA PI (Log10 MoM) 
3.1e-04  
(4.4e-07-0.21) 
0.015 
0.001 
(9.6e-07-0.29) 
0.019 
0.05 
(0.01-0.41) 
0.006 
0.05 
(0.01-0.58) 
0.017 
0.11 
(0.03-0.36) 
<0.0001 
0.11 
(0.03-0.43) 
0.001 
MAP (Log10 MoM) 
4.29e03  
(0.03-73.5e07) 
0.174   
8.6e12  
(1.7e11-4.5e14) 
<0.0001 
2.1e08  
(2.7e06-1.6e10) 
<0.0001 
160.1 
(18.7-1367.9) 
<0.0001 
  
Table 4. Biochemical and biophysical markers in pregnancies delivering by cesarean section for fetal distress and those delivering vaginally. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PLGF = placental growth factor; sFlt-1  = soluble fms-like tyrosine kinase-1; Ut PI = uterine artery pulsatility index; UA PI = umbilical artery pulsatility index; MCA PI = middle 
cerebral artery pulsatility index; MAP = mean arterial pressure; EFW = estimated fetal weight. Significance value adjusted for multiple comparisons with post hoc 
Bonferonni correction ** p<0.01; *** p<0.0001 
Biomarker 
Vaginal delivery 
(n=6,263) 
Cesarean section for fetal distress 
In labor 
(n=512) 
Before labor 
(n=30) 
Biochemical markers    
PlGF (MoM), median (IQR) 0.95 (0.58-1.51) 0.94 (0.52-1.58) 0.24 (0.11-0.42)*** 
PlGF < 5th percentile, n (%) 348 (4.6) 29 (5.7) 15 (50.0)*** 
PlGF < 10th percentile, n (%) 711 (9.4) 60 (11.7) 19 (63.3)*** 
    
sFlt -1 (MoM), median (IQR) 1.01 (0.74-1.39) 1.05 (0.79-1.52)** 3.55 (1.47-5.43)*** 
sFlt > 95th percentile, n (%) 328 (4.3) 42 (8.2)*** 18 (60.0)*** 
sFlt > 90th percentile, n (%) 693 (9.1) 77 (15.0)*** 21 (70.0)*** 
Biophysical markers    
Ut PI (MoM), median (IQR) 1.00 (0.85-1.17) 1.00 (0.86-1.18) 1.44 (1.01-2.14)*** 
Ut PI > 95th percentile, n (%) 355 (4.7) 33 (6.4) 12 (40.0)*** 
Ut PI > 90th percentile, n (%) 726 (9.0) 66 (12.9) 16 (53.3)*** 
    
UA PI (MoM), median (IQR) 1.02 (0.92-1.12) 1.03 (0.92-1.13) 1.14 (1.06-1.43)*** 
UA PI > 95th percentile, n (%) 370 (4.9) 26 (5.1) 10 (33.3)*** 
UA PI > 90th percentile, n (%) 746 (9.8) 56 (10.9) 12 (40.0)*** 
    
MCA PI (MoM), median (IQR) 1.02 (0.91-1.12) 1.04 (0.92-1.13) 0.96 (0.89-1.03)* 
MCA PI < 5th percentile, n (%) 379 (5.0) 27 (5.3) 3 (10.0) 
MCA PI < 10th percentile, n (%) 761 (10.0) 49 (9.6) 4 (13.3) 
    
MAP (MoM), median (IQR) 1.00 (0.95-1.05) 1.01 (0.95-1.06) 1.10 (0.99-1.21)*** 
MAP > 95th percentile, n (%) 331 (4.5) 34 (6.8) 14 (46.7)*** 
MAP > 90th percentile, n (%) 692 (9.4) 65 (13.0)* 14 (46.7)*** 
    
EFW percentile, median (IQR) 51.9 (28.3-75.8) 56.0 (31.7-80.4) 4.16 (0.16-8.96)*** 
EFW < 5th percentile, n (%) 279 (3.7) 19 (3.7) 15 (50.0)*** 
EFW < 10th percentile, n (%) 541 (7.1) 40 (7.8) 24 (80.0)*** 
Table 5. Univariable and multivariable logistic regression analysis in prediction of caesarean section for fetal distress before and during labor. 
 
 
 
EFW = estimated fetal weight;  PLGF = placental growth factor; sFlt-1  = soluble fms-like tyrosine kinase-1; Ut PI = uterine artery pulsatility index; UA PI = umbilical artery 
pulsatility index; MCA PI = middle cerebral artery pulsatility index; MAP = mean arterial pressure.  
Variable 
Cesarean section for fetal distress in labor Cesarean section for fetal distress before labor 
Univariable analysis Multivariable analysis Univariable analysis Multivariable analysis 
 OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value 
EFW Z-score 1.12 (1.02-1.22) 0.022 1.21 (1.02-1.23) 0.015 0.21 (0.16-0.29) <0.0001 0.26 (0.17-0.39) <0.0001 
PlGF (Log10 MoM) 0.83 (0.63-1.10) 0.201   0.01 (0.003-0.02) <0.0001   
sFlt -1 (Log10 MoM) 2.31 (1.52-3.51) <0.0001 2.36 (1.55-3.60) <0.0001 13.0e02 (3.3e02-51.5e02) <0.0001 2.1e02 (40.5-1.07e03) <0.0001 
Ut PI (Log10 MoM) 1.60 (0.72-3.57) 0.252   19.5e03 (16.2e02-23.4e04) <0.0001 1.2e03 (43.7-3.0e04) <0.0001 
UA PI (Log10 MoM) 1.57 (0.38-6.44) 0.534   11.6e08 (2.4e06-5.5e11) <0.0001 1.2e04 (14.3-10.5e06) 0.006 
MCA PI (Log10 MoM) 3.00 (0.66-13.72) 0.156   0.001 (4.0e-06-0.40) 0.023   
MAP (Log10 MoM) 20.13 (1.44-282.4) 0.026   1.05e15 (6.49e10-1.69e19) <0.0001   
Table 6. Biochemical and biophysical markers in pregnancies with and without low cord blood pH, low Apgar score at 5 minutes and admission 
to the neonatal unit. 
 
PLGF = placental growth factor; sFlt-1  = soluble fms-like tyrosine kinase-1; Ut PI = uterine artery pulsatility index; UA PI = umbilical artery pulsatility index; MCA PI = middle 
cerebral artery pulsatility index; MAP = mean arterial pressure; EFW = estimated fetal weight. Significance value adjusted for multiple comparisons with post hoc 
Bonferonni correction ** p<0.01; *** p<0.0001 
Biomarker 
Cord blood pH Apgar score at 5 minutes Neonatal unit admission 
Normal 
(n=3,244) 
Low 
(n=84) 
Normal 
(n=7,054) 
Low 
(n=70) 
No 
(n=7,721) 
Yes 
(n=524) 
Biochemical markers       
PlGF (MoM), median (IQR) 0.94 (0.57-1.52) 1.01 (0.49-1.49) 0.94 (0.57-1.50) 1.13 (0.56-1.71) 0.95 (0.58-1.51) 0.83 (0.40-1.47)*** 
PlGF < 5th percentile, n (%) 172 (5.3) 9 (10.7) 363 (5.1) 3 (4.3) 341 (4.4) 72 (13.7)*** 
PlGF < 10th percentile, n (%) 338 (10.4) 13 (15.5) 720 (10.2) 6 (8.6) 717 (9.3) 108 (20.6)*** 
       
sFlt -1 (MoM), median (IQR) 1.03 (0.75-1.44) 0.97 (0.73-1.27) 1.02 (0.75-1.40) 1.16 (0.78-1.57) 1.00 (0.74-1.38) 1.16 (0.85-1.71)*** 
sFlt > 95th percentile, n (%) 195 (6.0) 4 (4.8) 356 (5.0) 5 (7.1) 340 (4.4) 72 (13.7)*** 
sFlt > 90th percentile, n (%) 367 (11.3) 9 (10.7) 698 (9.9) 12 (17.1) 709 (9.2) 112 (21.4)*** 
Biophysical markers       
Ut PI (MoM), median (IQR) 1.00 (0.86-1.18) 1.01 (0.87-1.20) 1.00 (0.85-1.18) 0.98 (0.86-1.09) 1.00 (0.85-1.17) 1.02 (0.87-1.23)** 
Ut PI > 95th percentile, n (%) 187 (5.8) 6 (7.1) 370 (5.2) 2 (2.9) 361 (4.7) 50 (9.5)*** 
Ut PI > 90th percentile, n (%) 348 (10.7) 9 (10.7) 733 (10.4) 2 (2.9) 748 (9.7) 75 (14.3)** 
       
UA PI (MoM), median (IQR) 1.02 (0.91-1.13) 0.99 (0.90-1.11) 1.02 (0.91-1.12) 1.01 (0.89-1.12) 1.02 (0.91-1.12) 1.03 (0.92-1.15) 
UA PI > 95th percentile, n (%) 165 (5.1) 7 (8.3) 346 (4.9) 0 (0.0) 378 (4.9) 35 (6.7) 
UA PI > 90th percentile, n (%) 327 (10.1) 10 (11.9) 700 (9.9) 3 (4.3) 762 (9.9) 64 (12.2) 
       
MCA PI (MoM), median (IQR) 1.02 (0.92-1.12) 1.00 (0.92-1.09) 1.02 (0.91-1.12) 1.03 (0.90-1.13) 1.02 (0.91-1.12) 1.01 (0.91-1.11) 
MCA PI < 5th percentile, n (%) 170 (5.2) 5 (6.0) 356 (5.0) 3 (4.3) 388 (5.0) 23 (4.4) 
MCA PI < 10th percentile, n (%) 326 (10.0) 8 (9.5) 718 (10.2) 6 (8.6) 777 (10.1) 46 (8.8) 
       
MAP (MoM), median (IQR) 1.00 (0.95-1.06) 1.01 (0.94-1.06) 1.00 (0.95-1.06) 1.00 (0.92-1.04) 1.00 (0.95-1.05) 1.01 (0.95-1.07)* 
MAP > 95th percentile, n (%) 172 (5.5) 2 (2.4) 339 (4.9) 3 (4.4) 350 (4.7) 51 (10.0)*** 
MAP > 90th percentile, n (%) 328 (10.4) 8 (9.6) 685 (10.0) 6 (8.8) 725 (9.7) 75 (14.9)*** 
       
EFW percentile, median (IQR) 55.3 (30.5-78.6) 55.1 (29.6-73.6) 53.3 (29.0-77.6) 56.7 (23.5-86.5) 53.3 (29.1-77.5) 54.9 (24.7-78.3) 
EFW < 5th percentile, n (%) 127 (3.9) 3 (3.6) 272 (3.9) 3 (4.3) 284 (3.7) 43 (8.2)*** 
EFW < 10th percentile, n (%) 224 (6.9) 9 (10.7) 514 (7.3) 8 (11.4) 567 (7.3) 56 (10.7)** 
Table 7. Univariable logistic regression analysis in prediction of umbilical cord blood pH, low 5 minute Apgar score and univariable and 
multivariable logistic regression analysis in prediction of admission to neonatal unit. 
 
 
 
EFW = estimated fetal weight; PLGF = placental growth factor; sFlt-1  = soluble fms-like tyrosine kinase-1; Ut PI = uterine artery pulsatility index; UA PI = umbilical artery 
pulsatility index; MCA PI = middle cerebral artery pulsatility index; MAP = mean arterial pressure.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Variable 
Low cord blood pH Low 5 minute Apgar score Neonatal unit  admission 
Univariable analysis Univariable analysis Univariable analysis Multivariable analysis 
OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value 
EFW Z-score 0.92 (0.75-1.14) 0.450 1.09 (0.86-1.38) 0.481 0.96 (0.88-1.04) 0.316   
PlGF (Log10 MoM) 0.69 (0.37-1.32) 0.265 1.33 (0.63-2.80) 0.457 0.39 (0.30-0.51) <0.0001 0.58 (0.44-0.76) <0.0001 
sFlt -1 (Log10 MoM) 0.60 (0.22-1.64) 0.322 2.22 (0.77-6.40) 0.142 6.37 (4.32-9.39) <0.0001 4.77 (3.19-7.14) <0.0001 
Ut PI (Log10 MoM) 1.95 (0.30-12.49) 0.482 0.33 (0.04-2.79) 0.308 5.25 (2.46-11.22) <0.0001 3.37 (1.58-7.18) 0.002 
UA PI (Log10 MoM) 0.82 (0.03-22.72) 0.909 0.09 (0.003-3.36) 0.194 4.69 (1.17-18.82) 0.029   
MCA PI (Log10 MoM) 0.16 (0.01-5.39) 0.306 4.10 (0.08-219.22) 0.487 0.61 (0.14-2.66) 0.513   
MAP (Log10 MoM) 2.68 (0.01-13.26) 0.755 0.01 (0.00-9.63) 0.190 103.8 (8.02-13.43e03) <0.0001   
